Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab

被引：115
|
作者：
Barnett, Richard [1 ]
Barta, Valerie S. [1 ]
Jhaveri, Kenar D. [1 ]
机构：
[1] Hofstra Northwell Sch Med, Hempstead, NY 11549 USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2017年 / 376卷 / 02期
关键词：
IPILIMUMAB; MELANOMA;
D O I：
10.1056/NEJMc1614298
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：191 / 192
页数：2
相关论文
共 50 条
  • [1] Successful treatment of refractory leiomyosarcoma with the PD-1 inhibitor nivolumab
    Heine, A.
    Kristiansen, G.
    Schild, H. H.
    Brossart, P.
    ANNALS OF ONCOLOGY, 2016, 27 (09) : 1813 - 1814
  • [2] Fatal Myocarditis Following Treatment with the PD-1 Inhibitor Nivolumab
    Matson, Daniel R.
    Accola, Molly A.
    Rehrauer, William M.
    Corliss, Robert F.
    JOURNAL OF FORENSIC SCIENCES, 2018, 63 (03) : 954 - 957
  • [3] Nivolumab: targeting PD-1 to bolster antitumor immunity
    Brahmer, Julie R.
    Hammers, Hans
    Lipson, Evan J.
    FUTURE ONCOLOGY, 2015, 11 (09) : 1307 - 1326
  • [4] Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
    Guo, Liting
    Zhang, Haijun
    Chen, Baoan
    JOURNAL OF CANCER, 2017, 8 (03): : 410 - 416
  • [5] Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma
    Ivashko, Igor N.
    Kolesar, Jill M.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (04) : 193 - 201
  • [6] Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
    Zhang, Min
    Liu, Kehai
    Wang, Mingfu
    RSC ADVANCES, 2019, 9 (58) : 33903 - 33911
  • [7] Targeting the PD-1 pathway: a promising future for the treatment of melanoma
    Andrew Mamalis
    Manveer Garcha
    Jared Jagdeo
    Archives of Dermatological Research, 2014, 306 : 511 - 519
  • [8] Targeting the PD-1 pathway: a promising future for the treatment of melanoma
    Mamalis, Andrew
    Garcha, Manveer
    Jagdeo, Jared
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2014, 306 (06) : 511 - 519
  • [9] Harnessing the PD-1 Pathway in Renal Cell Carcinoma: Current Evidence and Future Directions
    Abhishek Tripathi
    Charles G. Drake
    Lauren C. Harshman
    BioDrugs, 2014, 28 : 513 - 526
  • [10] Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable
    Prasad, Vinay
    Kaestner, Victoria
    SEMINARS IN ONCOLOGY, 2017, 44 (02) : 132 - 135
12345